Kiniksa Pharmaceuticals International (KNSA) Leases (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Leases for 5 consecutive years, with $9.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 5.48% year-over-year to $9.8 million, compared with a TTM value of $9.8 million through Dec 2025, down 5.48%, and an annual FY2025 reading of $9.8 million, down 5.48% over the prior year.
- Leases was $9.8 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $10.1 million in the prior quarter.
- Across five years, Leases topped out at $13.2 million in Q2 2023 and bottomed at $4.1 million in Q2 2022.
- Average Leases over 5 years is $8.6 million, with a median of $9.9 million recorded in 2025.
- The sharpest move saw Leases fell 24.45% in 2022, then soared 224.18% in 2023.
- Year by year, Leases stood at $5.6 million in 2021, then decreased by 2.97% to $5.4 million in 2022, then soared by 121.56% to $11.9 million in 2023, then dropped by 13.03% to $10.4 million in 2024, then dropped by 5.48% to $9.8 million in 2025.
- Business Quant data shows Leases for KNSA at $9.8 million in Q4 2025, $10.1 million in Q3 2025, and $10.3 million in Q2 2025.